All In Biotech

Drug Trial Radar · NCT03896685

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Apr 6, 2020

Primary completion

Oct 4, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Médecins Sans Frontières, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Partners in Health; Harvard Medical School (HMS and HSDM); Epicentre; Institute of Tropical Medicine, Belgium; Socios En Salud, Peru; Interactive Research and Development; University of San Francisco
First posted
Apr 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

Conditions

  • Tuberculosis, Multidrug-Resistant
  • Tuberculosis
  • Pulmonary Tuberculoses
  • Mycobacterial Infections
  • Bacterial Infections
  • Gram-Positive Bacterial Infections

Interventions

  • Bedaquiline 100 MGDrug

    Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week

  • Delamanid 50 MG Oral TabletDrug

    Delamanid: 100 mg BID

  • Clofazimine 100 MG Oral CapsuleDrug

    Clofazimine: 100 mg QD

  • Linezolid 600Mg TabDrug

    Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization

  • Control arm MDR-TB regimen, designed according to latest WHO guidelinesDrug

    Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Week 73 Efficacy: Proportion of participants with favorable outcome at Week 73Time frame: Week 73 after randomization

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • Aundh Chest Hospital

    Pune, India

  • National Center for Tuberculosis Problems

    Almaty, Kazakhstan

  • State Municipal Enterprise on the right of economic management "City Centre of Phthisiopulmonology" of Nur-sultan city's administration

    Almaty, Kazakhstan

  • Partners In Health Lesostho

    Maseru, Lesotho

  • The Indus Hospital

    Karachi, Pakistan

  • Institute of Chest Disease,

    Kotri, Pakistan

  • Centro de Investigación del Hospital Nacional Hipólito Unanue

    Lima, Peru

  • Centro de Investigación de Enfermedades Neumológicas del Hospital Nacional Sergio Bernales

    Lima, Peru

  • Hanoi Lung Hospital

    Hanoi, Vietnam

  • Pham Ngoc Thach Hospital

    Ho Chi Minh City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.